Buprenorphine Dose Escalation Trial for Treatment of Non-Dependent Opiate Users - 2

This will be an open-label, single dose-escalation trial. A total of 24 opiate experienced, but not dependent subjects will receive four ascending doses of buprenorphine, 4, 8, 16, and 24 mg, respectively, with an at least a 14 day washout interval between treatments. The four treatments are sublingual administration of: 1. two 2-mg buprenorphine sublingual tablets, 2. one 8-mg buprenorphine sublingual tablet, 3. two 8-mg buprenorphine sublingual tablets; and 4. three 8-mg buprenorphine sublingual tablets. The dose proportionality in plasma profiles of buprenorphine and dose response of the buprenorphine sublingual tablets are evaluated at buprenorphine dose range of 4 to 24 mg.